Clinical Trial Update: Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 2/3 study comparing Letrozole plus low-dose metronomic capecitabine versus EC-T (epirubicin/cyclophosphamide follow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Cytoxan (cyclophosphamide)
• ELLENCE (Epirubicin hydrochloride)
• FEMARA (letrozole)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Breast Cancer | Phase 2, Phase 3 | Status: UNKNOWN